Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
1994-4-19
|
| pubmed:abstractText |
Immunization with disease-associated TCR V region peptides is an effective treatment for experimental autoimmune encephalomyelitis. Myelin basic protein-specific T cells, which induce experimental autoimmune encephalomyelitis in many animal strains, may be important in the pathogenesis of multiple sclerosis. Myelin basic protein-specific T cell clones from some multiple sclerosis patients preferentially use TCR V genes from the V beta 5.2 and V beta 6.1 families. To assess the safety and immunogenicity of TCR V beta 5.2 and V beta 6.1 peptides, we injected 11 multiple sclerosis patients with varying doses of two synthetic peptides, TCR V beta 5.2(39-59) and V beta 6.1(39-59), encompassing the CDR2 region of these V gene families. Low doses (100 to 300 micrograms) of peptide induced T cell immunity in 7 of 11 patients to one or both peptides. Delayed type hypersensitivity skin responses to the peptides were observed in three of seven responders, and TCR peptide-specific Ab occurred in two of seven T cell responders. Low doses of TCR peptides produced no side effects and did not cause broad spectrum immunosuppression. Synthetic TCR V region peptides can induce T cell immunity safely in humans and may prove useful in treating human autoimmune diseases.
|
| pubmed:grant | |
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
0022-1767
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
1
|
| pubmed:volume |
152
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
2510-9
|
| pubmed:dateRevised |
2007-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:7510746-Adult,
pubmed-meshheading:7510746-Aged,
pubmed-meshheading:7510746-Amino Acid Sequence,
pubmed-meshheading:7510746-Epitopes,
pubmed-meshheading:7510746-Female,
pubmed-meshheading:7510746-Humans,
pubmed-meshheading:7510746-Hypersensitivity, Delayed,
pubmed-meshheading:7510746-Immunization,
pubmed-meshheading:7510746-Immunologic Techniques,
pubmed-meshheading:7510746-Immunotherapy,
pubmed-meshheading:7510746-Male,
pubmed-meshheading:7510746-Middle Aged,
pubmed-meshheading:7510746-Molecular Sequence Data,
pubmed-meshheading:7510746-Multiple Sclerosis,
pubmed-meshheading:7510746-Myelin Basic Proteins,
pubmed-meshheading:7510746-Peptide Fragments,
pubmed-meshheading:7510746-Receptors, Antigen, T-Cell, alpha-beta,
pubmed-meshheading:7510746-T-Lymphocytes
|
| pubmed:year |
1994
|
| pubmed:articleTitle |
Immunity to TCR peptides in multiple sclerosis. I. Successful immunization of patients with synthetic V beta 5.2 and V beta 6.1 CDR2 peptides.
|
| pubmed:affiliation |
Veterans Affairs Medical Center, Portland, OR 97201.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Research Support, U.S. Gov't, Non-P.H.S.,
Controlled Clinical Trial,
Research Support, Non-U.S. Gov't
|